All In MedTech

FDA Clearance Tracker · P960009-S478

Activa®, Percept™ and SenSight™ Deep Brain Stimulation Therapy System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 20, 2025

Approved

Time to decision

309 days

Received Apr 17, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P960009-S478
Device name
Activa®, Percept™ and SenSight™ Deep Brain Stimulation Therapy System
Applicant location
Minneapolis, MN
Received
Apr 17, 2024
Decided
Feb 20, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P960009

Device type

Device class
Class III

Every decision under product code NHL

FDA's approval statement

As written in FDA's record.

for a new optional programming feature called adaptive deep brain stimulation (aDBS). This device is indicated for bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) using Medtronic DBS Therapy for Parkinson's Disease is indicated for adjunctive therapy in reducing some of the symptoms in individuals with levodopa-responsive Parkinson's disease of at least 4 years’ duration that are not adequately controlled with medication, including motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.